Journal article
Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111
Journal of clinical microbiology, Vol.54(3), pp.662-665
03/2016
DOI: 10.1128/JCM.03019-15
PMCID: PMC4768001
PMID: 26719434
Abstract
ME1111 is a novel small molecule antifungal agent under development for the topical treatment of onychomycosis. Standardization of the susceptibility testing method for this candidate antifungal is needed. Toward this end, 8 independent laboratories determined the interlaboratory reproducibility of ME1111 susceptibility testing. In addition, we subsequently identified 2 strains as quality control (QC) isolates for the method. In the reproducibility study, 5 blinded clinical strains each of Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum were tested, while the QC study tested 6 blinded T. rubrum or T. mentagrophytes ATCC strains. Testing was performed in frozen microtiter panels according to the Clinical and Laboratory Standards Institute (CLSI) M38-A2 methodology. In the reproducibility study, 9 of 15 clinical strains showed interlaboratory agreement of >90% at the 80% inhibition endpoint, with a range of agreement of 76.2% to 100%. In the QC study, 4 of the 6 ATCC strains showed interlaboratory agreement of >90%. ME1111 demonstrated excellent interlaboratory agreement when tested against dermatophytes. Based on this data, the CLSI Subcommittee on Antifungal Susceptibility Tests approved the susceptibility testing of ME1111 against dermatophytes according to M38-A2 methodology, which stipulates RPMI 1640 as the test medium, an inoculum size of 1 to 3 × 10(3) CFU/ml, and an incubation time and temperature of 96 h at 35°C. The MIC endpoint should be 80% inhibition compared with the growth control. T. rubrum ATCC MYA-4438 and T. mentagrophytes ATCC 28185 were selected as QC isolates, with an acceptable range of 0.12 to 1 μg/ml for the two strains.
Details
- Title: Subtitle
- Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111
- Creators
- M Ghannoum - Case Western Reserve University, Cleveland, Ohio, USA mahmoud.ghannoum@case.eduV Chaturvedi - Wadsworth Center, New York State Department of Health, Albany, New York, USAD Diekema - University of Iowa Carver College of Medicine, Iowa City, Iowa, USAL Ostrosky-Zeichner - University of Texas Health Science Center at Houston, Houston, Texas, USAR Rennie - University of Alberta Hospital, Edmonton, Alberta, CanadaT Walsh - Weill Cornell Medical Center, New York, New York, USAN Wengenack - Mayo Clinic, Rochester, Minnesota, USAA Fothergill - University of Texas Health Science Center at San Antonio, San Antonio, Texas, USAN Wiederhold - University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
- Resource Type
- Journal article
- Publication Details
- Journal of clinical microbiology, Vol.54(3), pp.662-665
- Publisher
- United States
- DOI
- 10.1128/JCM.03019-15
- PMID
- 26719434
- PMCID
- PMC4768001
- ISSN
- 0095-1137
- eISSN
- 1098-660X
- Grant note
- DOI: 10.13039/501100004169, name: Meiji Seika Pharma
- Language
- English
- Date published
- 03/2016
- Academic Unit
- Infectious Diseases; Pathology; Internal Medicine
- Record Identifier
- 9984001247802771
Metrics
23 Record Views